New Delhi: GSK has raised 978 million pounds ($1.24 billion) from a discounted sale of a stake in its spun-off consumer healthcare business Haleon, the British drugmaker said on Wednesday.
GSK sold around 300 million shares in Haleon at 326 pence per share, cutting its shareholding in the world’s largest standalone consumer healthcare company to 4.2per cent.
The disposal marks the third time GSK is selling a stake in the Sensodyne toothpaste maker in less than a year, reducing its holding from the 12.9per cent stake initially retained in the business.
Haleon was formed in 2019 by merging GSK and Pfizer’s consumer healthcare businesses. Pfizer holds a 32per cent stake in Haleon, according to GSK.
GSK had raised 885.6 million pounds ($1.12 billion) from a discounted stake sale in Haleon in October last year.
continued below
After Wednesday’s sale, GSK could remain the second largest shareholder in Advil-maker Haleon, according to LSEG data.
GSK had earlier said that the Haleon spin-off and subsequent stake sales would allow the company to sharpen its focus on vaccines and infectious diseases and fund deals to bolster a lacklustre drug pipeline.
Shares in Haleon closed at 333.6 pence, while GSK closed at 1,581 pence at the end of Tuesday’s trading. ($1 = 0.7916 pounds)
Most Read in Pharma Industry
Join the community of 2M+ industry professionals
Subscribe to our newsletter to get latest insights & analysis.
Download ETHealthworld App
- Get Realtime updates
- Save your favourite articles
Source link
credite